Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors

Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors

T cell engaging therapies, like CAR-T cells and T cell engagers, redirect T cells toward tumor cells, facilitating the formation of a cytotoxic synapse and resulting in subsequent tumor cell killing. T cell receptor or CAR-T downstream signaling triggers a release of pro-inflammatory cytokines, whic...

Full description

Bibliographic Details
Main Authors: Gabrielle Leclercq, Nathalie Steinhoff, Hélène Haegel, Donata De Marco, Marina Bacac, Christian Klein
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:OncoImmunology
Subjects:
Chimeric antigen receptor-(CAR-) T cells
T cell engagers
CD3 bispecific antibody
cytokine release syndrome (CRS)
cytokines
tyrosine kinase inhibitors
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2022.2083479

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2022.2083479

Similar Items